OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OPRX OptimizeRx Corporation

Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST

12.15

-0.45

-3.57%

盘后12.29

+0.14+1.15%

18:49 EST

High12.60	Low12.03	Vol225.81K
Open12.60	D1 Closing12.60	Amplitude4.56%
Mkt Cap226.48M	Tradable Cap173.93M	Total Shares18.64M
T/O2.76M	T/O Rate1.58%	Tradable Shares14.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OPRX","market":"US","secType":"STK","nameCN":"OptimizeRx Corporation","latestPrice":12.15,"timestamp":1768597200000,"preClose":12.6,"halted":0,"volume":225807,"hourTrading":{"tag":"盘后","latestPrice":12.29,"preClose":12.15,"latestTime":"18:49 EST","volume":41607,"amount":508378.59,"timestamp":1768607363584,"change":0.14,"changeRate":0.011523,"amplitude":0},"delay":0,"changeRate":-0.03571428571428566,"floatShares":14315107,"shares":18640652,"eps":0.001838,"marketStatus":"Closed Martin Luther King, Jr. Day","change":-0.45,"latestTime":"01-16 16:00:00 EST","open":12.6,"high":12.6,"low":12.025,"amount":2758878.31302,"amplitude":0.045635,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.001838,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.6,"preHourTrading":{"tag":"盘前","latestPrice":12.32,"preClose":12.6,"latestTime":"08:53 EST","volume":268,"amount":3292.039774,"timestamp":1768571607322,"change":-0.28,"changeRate":-0.022222,"amplitude":0.003175},"postHourTrading":{"tag":"盘后","latestPrice":12.29,"preClose":12.15,"latestTime":"18:49 EST","volume":41607,"amount":508378.59,"timestamp":1768607363584,"change":0.14,"changeRate":0.011523,"amplitude":0},"volumeRatio":1.1142599131614879,"impliedVol":0.6662,"impliedVolPercentile":0.2869},"requestUrl":"/m/hq/s/OPRX/wiki","defaultTab":"wiki","newsList":[{"id":"2601617663","title":"The 13% return this week takes OptimizeRx's (NASDAQ:OPRX) shareholders one-year gains to 156%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601617663","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601617663?lang=en_us&edition=fundamental","pubTime":"2026-01-08 18:57","pubTimestamp":1767869835,"startTime":"0","endTime":"0","summary":"It hasn't been the best quarter for OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders, since the share price has...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-oprx/optimizerx/news/the-13-return-this-week-takes-optimizerxs-nasdaqoprx-shareho","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-oprx/optimizerx/news/the-13-return-this-week-takes-optimizerxs-nasdaqoprx-shareho","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","USJW.SI","NQmain","OPRX","PSQ","BK4167","TSYW.SI","NVIW.SI","USAW.SI","MNQmain","SQQQ","QID",".IXIC","TQQQ"],"gpt_icon":1},{"id":"2601806821","title":"BRIEF-Optimizerx And Experian Collaborate To Improve Privacy-Safe Identity Resolution In Healthcare Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806821","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806821?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:44","pubTimestamp":1767793471,"startTime":"0","endTime":"0","summary":"BRIEF-Optimizerx And Experian Collaborate To Improve Privacy-Safe Identity Resolution In Healthcare MarketingJan 7 (Reuters) - OPTIMIZERx Corp OPRX.O:OPTIMIZERX AND EXPERIAN COLLABORATE TO IMPROVE PRI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2TJN9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2601803184","title":"OptimizeRx Partners with Experian to Enhance Privacy-Safe Healthcare Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803184","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803184?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790862,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation has announced a collaboration with Experian to enhance privacy-safe identity resolution in healthcare marketing. This partnership integrates OptimizeRx's patented Micro-Neighborhood audience technology with Experian's robust identity graph, enabling life science companies and healthcare marketing agencies to reach and measure consumer audiences more accurately and at greater scale. The collaboration aims to reduce onboarding loss, improve audience quality, and deliver more transparent, privacy-forward campaign performance for direct-to-consumer initiatives in the healthcare sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL34cH8m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1273509221.SGD","BK4112","BK5064","BK4585","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2108987350.USD","IE00B64PRP62.GBP","LU0061474960.USD","NDAQ","LU1228905037.USD","SG9999014021.USD","LU0957791311.USD","BK4588","LU0997586515.USD","BK4167","LU1815333072.USD","LU2125909916.SGD","LU0171293334.USD","SG9999014039.USD","IE00BKPKM429.USD","OPRX","LU2210149790.SGD","LU2095319765.USD","LU0786609619.USD","LU0096362180.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU1228905540.USD","EXPN.UK","LU1196032939.SGD","LU1923622291.USD","LU0390134368.USD","LU2125909759.SGD","SG9999014013.SGD","LU2210150020.SGD","LU0545562505.USD","LU1104425308.USD","LU0960981461.USD"],"gpt_icon":0},{"id":"2601803641","title":"OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803641","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803641?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:00","pubTimestamp":1767790804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2TJN9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2593363314","title":"OptimizeRx Chief Finance & Strategy Officer Edward Stelmakh Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593363314","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593363314?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:11","pubTimestamp":1766416275,"startTime":"0","endTime":"0","summary":"Edward Stelmakh, Chief Finance & Strategy Officer of OptimizeRx Corporation, reported a disposal of common shares of OptimizeRx Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5Nzg5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OptimizeRx Chief Finance & Strategy Officer Edward Stelmakh Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2592993256","title":"OptimizeRx Secures Exclusive Multi-Year Partnerships to Expand Point-of-Care Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2592993256","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592993256?lang=en_us&edition=fundamental","pubTime":"2025-12-17 17:30","pubTimestamp":1765963811,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation has announced four new partner agreements that significantly expand its in-workflow point-of-care  network and increase its National Provider Identifier  reach by 37%. Among these agreements is an exclusive, multi-year partnership with a high-demand e-prescribing  platform that was previously only available through a competitor. The company also secured multi-year renewals with two top-performing electronic health record  and eRx partners, with one of these agreements establishing exclusivity. Additionally, OptimizeRx has entered a new partnership that extends its reach into the point-of-discharge setting and broadens access to healthcare providers through an expanded network of EHR platforms. These partnerships reinforce OptimizeRx's leadership in the POC marketing landscape and position the company for sustained growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL6sDZR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","NDAQ","BK4588","BK4112","LU2210150020.SGD","BK4167","OPRX","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2590937365","title":"Halozyme Therapeutics Elects Jim Lang to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590937365?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227935,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics Inc. has announced the election of Jim Lang to its Board of Directors. Lang brings over 30 years of executive experience in healthcare, life sciences, business services, and data analytics. He currently serves on the boards of Biovie, Inc., OptimizeRx Corporation, and EVERSANA, where he was most recently CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbYFWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO","BIVI","BK4167","OPRX"],"gpt_icon":0},{"id":"2584929331","title":"OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929331","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929331?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571484,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - OPTIMIZERx Q3 adjusted net income USD 3.9 million vs. IBES estimate USD 977.8 thousand.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:01:46.553 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD20RGM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2584950483","title":"OptimizeRx Unveils Presentation Showcasing Technology Solutions for Patient Engagement and Pharma Connectivity","url":"https://stock-news.laohu8.com/highlight/detail?id=2584950483","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584950483?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:59","pubTimestamp":1763492376,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation has released a new corporate presentation highlighting its role as a technology provider facilitating engagement between life sciences organizations, physicians, and patients. The presentation details the company's technology platform and nationwide patient point-of-care network, which connects a large proportion of U.S. physicians and patients. OptimizeRx reports a workforce of approximately 130 employees across the United States and Croatia, with an average revenue per full-time employee exceeding $700,000. Key financial details include a reported market capitalization of around $301 million, a share price of $16.15, cash and cash equivalents totaling $19.5 million, and total debt of $28.1 million. The company is listed on the NASDAQ under the ticker OPRX. The presentation also describes the company's AI-driven platform designed to address brand visibility challenges in the pharmaceutical sector, using a variety of digital and direct outreach channels to connec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLm27wK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2584952222","title":"Stifel Nicolaus Remains a Buy on OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584952222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584952222?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:36","pubTimestamp":1763487392,"startTime":"0","endTime":"0","summary":"In a report released on November 14, David Grossman from Stifel Nicolaus maintained a Buy rating on OptimizeRx, with a price target of $24.83. Acco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-optimizerx-oprx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-optimizerx-oprx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4167","SF","OPRX"],"gpt_icon":0},{"id":"2584415625","title":"OptimizeRx Is Maintained at Equal-Weight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584415625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584415625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:05","pubTimestamp":1763384700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:05 ET (13:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2582487064","title":"OptimizeRx Corporation Files Initial Beneficial Ownership Statement for Brendan W. Merrell, Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582487064","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582487064?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:55","pubTimestamp":1762786539,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Brendan W. Merrell, Chief Operating Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL4Qz6b4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"1112743893","title":"OptimizeRx Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Partnerships and Predictable Revenue Model","url":"https://stock-news.laohu8.com/highlight/detail?id=1112743893","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112743893?lang=en_us&edition=fundamental","pubTime":"2025-11-10 13:06","pubTimestamp":1762751192,"startTime":"0","endTime":"0","summary":"[Management View]OptimizeRx management presented upgraded guidance methodologies, now anchored exclusively to contracted revenues and recurring client business streams instead of pipeline...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0},{"id":"2582846777","title":"OptimizeRx (OPRX) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2582846777","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582846777?lang=en_us&edition=fundamental","pubTime":"2025-11-10 13:04","pubTimestamp":1762751085,"startTime":"0","endTime":"0","summary":"DATEThursday, November 6, 2025 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Steve SilvestroChief Financial Officer — Edward StelmakhChief Commercial Officer — Teresa GrecoPresident — Andy Chief Operating Officer — Jim DwyerNeed a quote from a Motley Fool analyst?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/optimizerx-oprx-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/optimizerx-oprx-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["OPRX"],"gpt_icon":0},{"id":"2581878378","title":"OptimizeRx Down Over 17%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581878378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581878378?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:08","pubTimestamp":1762531680,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation  is currently at $15.69, down $3.25 or 17.16%. --Would be lowest close since Aug. 20, 2025, when it closed at $15.49. --On pace for largest percent decrease since Nov. 14, 2024, when it fell 33.98%. --Currently down two consecutive days; down 18.11% over this period. --Down 23.43% this week; worst weekly performance since the week ending Nov. 15, 2024, when it fell 39.09%. --Up 222.84% year-to-date; on pace for best year since 1999, when it rose 1600%. --Down 99.99% from its all-time closing high of $106249.23 on May 17, 2005. --Up 149.84% from 52 weeks ago , when it closed at $6.28. --Traded as low as $15.01; lowest intraday level since Aug. 8, 2025, when it hit $14.31. --Down 20.75% at today's intraday low; largest intraday percent decrease since Nov. 14, 2024, when it fell as much as 35.77%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2581886444","title":"OptimizeRx Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886444?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:09","pubTimestamp":1762524540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 09:09 ET (14:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2581012793","title":"OptimizeRx reports Q3 revenue of $26.1 million, up 22% year-over-year","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012793?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462925,"startTime":"0","endTime":"0","summary":"OptimizeRx Corporation reported third quarter 2025 revenue of $26.1 million, a 22% increase year-over-year. Gross profit for the quarter rose 30% to $17.5 million. Non-GAAP net income was $3.9 million, or $0.20 per diluted share, compared to $2.3 million, or $0.12 per diluted share, in the third quarter of 2024. Adjusted EBITDA reached $5.1 million, up from $2.7 million in the same period last year. Cash, cash equivalents, and short-term investments totaled $19.5 million as of September 30, 2025. The company increased its full-year 2025 guidance to a revenue range of $105 million to $109 million and adjusted EBITDA of $16 million to $19 million. For 2026, OptimizeRx introduced revenue guidance of $118 million to $124 million and adjusted EBITDA of $19 million to $22 million. The company paid off an additional $2 million in principal from its term loan after the end of the third quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL626437:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","OPRX","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4167"],"gpt_icon":0},{"id":"2581012763","title":"BRIEF-OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012763","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012763?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462906,"startTime":"0","endTime":"0","summary":"Nov 06  - OPTIMIZERx Q3 adjusted net income USD 3.9 million vs. IBES estimate USD 977.8 thousand.Q3 adjusted EBITDA USD 5.1 million vs. IBES estimate USD 1.86 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXA58EF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2581901224","title":"OptimizeRx Q3 Gross Profit USD 17.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581901224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581901224?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462861,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXA58EF6:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2581017810","title":"OptimizeRx Corp - Introduces 2026 Revenue Guidance $118-$124 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581017810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581017810?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXA58EF6:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.optimizerx.com","stockEarnings":[{"period":"1week","weight":-0.0767},{"period":"1month","weight":-0.0732},{"period":"3month","weight":-0.3785},{"period":"6month","weight":-0.0632},{"period":"1year","weight":1.5},{"period":"ytd","weight":-0.009}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.057598},{"month":2,"riseRate":0.571429,"avgChangeRate":0.038318},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.002984},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.055919},{"month":5,"riseRate":0.571429,"avgChangeRate":0.132195},{"month":6,"riseRate":0.857143,"avgChangeRate":0.069942},{"month":7,"riseRate":0.25,"avgChangeRate":-0.03341},{"month":8,"riseRate":0.625,"avgChangeRate":0.055887},{"month":9,"riseRate":0.5,"avgChangeRate":0.066303},{"month":10,"riseRate":0.375,"avgChangeRate":-0.045261},{"month":11,"riseRate":0.5,"avgChangeRate":0.019799},{"month":12,"riseRate":0.25,"avgChangeRate":-0.029069}],"exchange":"NASDAQ","name":"OptimizeRx Corporation","nameEN":"OptimizeRx Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OptimizeRx Corporation,OPRX,OptimizeRx Corporation股票,OptimizeRx Corporation股票老虎,OptimizeRx Corporation股票老虎国际,OptimizeRx Corporation行情,OptimizeRx Corporation股票行情,OptimizeRx Corporation股价,OptimizeRx Corporation股市,OptimizeRx Corporation股票价格,OptimizeRx Corporation股票交易,OptimizeRx Corporation股票购买,OptimizeRx Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction